Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Dermatology and Therapy"
DOI: 10.1007/s13555-021-00596-8
Abstract: Deucravacitinib, a novel, oral, selective inhibitor of tyrosine kinase 2 (TYK2) signaling, acts via an allosteric mechanism by binding to the enzyme’s regulatory domain instead of the catalytic domain. This unique binding provides high functional… read more here.
Keywords: jak; kinase; inhibition; tyk2 ... See more keywords
TYK2 inhibition: changing the treatment landscape for psoriasis?
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2008240
Abstract: Psoriasis is a common immune-mediated inflammatory disease affecting approximately 2% of individuals living in Western countries. Patients with psoriasis suffer from a multitude of comorbidities such as psoriatic arthritis, inflammatory bowel disease, anxiety and depression,… read more here.
Keywords: tyk2; psoriasis; deucravacitinib; poetyk pso ... See more keywords
First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13435
Abstract: This randomized, double‐blind, single‐ and multiple‐ascending dose study assessed the pharmacokinetics (PKs), pharmacodynamics, and safety of deucravacitinib (Sotyktu™), a selective and potent small‐molecule inhibitor of tyrosine kinase 2, in 100 (75 active, 25 placebo) healthy… read more here.
Keywords: small molecule; selective potent; inhibitor tyrosine; molecule inhibitor ... See more keywords
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-221664
Abstract: Objective To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). Methods In this double-blind, phase II trial, 203 patients with PsA… read more here.
Keywords: safety; deucravacitinib; inhibitor deucravacitinib; tyk2 inhibitor ... See more keywords
POS0198 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.2603
Abstract: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates signaling by key cytokines involved in psoriatic arthritis (PsA) and plaque psoriasis (PsO) pathogenesis. Deucravacitinib is a novel oral agent that selectively inhibits TYK2 via… read more here.
Keywords: deucravacitinib; pbo; myers squibb; bristol myers ... See more keywords
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
Sign Up to like & getrecommendations! Published in 2023 at "Immunotherapy"
DOI: 10.2217/imt-2023-0062
Abstract: WHAT IS THIS SUMMARY ABOUT? This is a summary of a paper published in a medical journal that describes the results of a study called POETYK PSO-2, which investigated a new treatment for plaque psoriasis.… read more here.
Keywords: deucravacitinib; poetyk pso; plaque psoriasis; treatment ... See more keywords